Added to YB: 2025-01-13
Pitch date: 2025-01-12
VERU [bullish]
Veru Inc.
-69.17%
current return
Author Info
No bio for this author
Company Info
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS).
Market Cap
$47.6M
Pitch Price
$7.85
Price Target
5.00 (+107%)
Dividend
N/A
EV/EBITDA
-0.98
P/E
-1.70
EV/Sales
2.15
Sector
Pharmaceuticals
Category
growth
Veru Inc. (VERU): Potential Multi-Bagger with Phase 2b Readout on the Horizon
VERU: Ph2b readout for enobosarm+semaglutide combo imminent. $5 PT (+541%). $114M mcap, $35M cash. Preserves lean mass lost w/ GLP-1s. 27 studies, 1600 pts, safe. $1.75B peak sales est. Risks: approval, mgmt credibility. Competing w/ BHVN, SRRK, REGN, KROS. Undervalued vs peers.
Read full article (3 min)